Evidence map›Paper›PMID 24361676›Full record

ReviewBiochimica et biophysica acta2014

Doxorubicin, DNA torsion, and chromatin dynamics.

Fan Yang, Sheila S Teves, Christopher J Kemp, Steven Henikoff

Abstract readReview
In one paragraph

Review in Biochimica et biophysica acta, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 300 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
300citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

300 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Impact of CaInternational journal of molecular sciences · 2026
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

240 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fan YangBasic Science Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Sheila S TevesBasic Science Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Christopher J KempHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. Electronic address: cjkemp@fhcrc.org.
Steven HenikoffBasic Science Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Howard Hughes Medical Institute, Seattle, WA 98109, USA. Electronic address: steveh@fhcrc.org.

Funding

Trans-NetworkU54CA143862 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI DAVIES, PAUL · 2009 to 2013
$8.4M
Epigenomic profiling of histone turnover kinetics in mammalian cellsR01ES020116 · NIEHS · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HENIKOFF, STEVEN · 2010 to 2014
$2.4M
Howard Hughes Medical InstituteNCI NIH HHS U54 CA143862NIEHS NIH HHS R01 ES020116
6 · The paper itself

Abstract

Doxorubicin is one of the most important anti-cancer chemotherapeutic drugs, being widely used for the treatment of solid tumors and acute leukemias. The action of doxorubicin and other anthracycline drugs has been intensively investigated during the last several decades, but the mechanisms that have been proposed for cell killing remain disparate and controversial. In this review, we examine the proposed models for doxorubicin action from the perspective of the chromatin landscape, which is altered in many types of cancer due to recurrent mutations in chromatin modifiers. We highlight recent evidence for effects of anthracyclines on DNA torsion and chromatin dynamics that may underlie basic mechanisms of doxorubicin-mediated cell death and suggest new therapeutic strategies for cancer treatment.

Indexed as

AnimalsAntibiotics, AntineoplasticChromatinDNADoxorubicinHumansNucleosomesOxidative StressAntibiotics, AntineoplasticChromatinDNADoxorubicinNucleosomesAnthracyclineCancerChemotherapyChromatin dynamicsDNA torsionDoxorubicin

Identifiers

PMID24361676
PMCPMC3927826

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.